Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib alone or in combination with rituximab produces superior progression free survival (PFS) compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia (CLL): results of Alliance North American Intergroup Study A041202. ASH Annual Meeting and Exposition 2018, abstract 6.
Derde generatie anti-CD19 CAR T-cellen voor gerecidiveerde/refractaire CLL
jan 2025 | Leukemie, Lymfoom